Michael Gelband’s Veradermics Inc MANE Stock Holding History

Michael Gelband’s Portfolio MANE Stock Details MANE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,358	Closed	-$212K	–	2215
2026 Q1	$212K	Buy	+3,358	New	+$169K	﹤0.01%	1369

Other funds holding MANE

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Michael Gelband's MANE Position: Q2 2026 in Review

Michael Gelband sold out of Veradermics Inc (MANE) in Q2 2026, closing a stake of 3,358 shares — an estimated $212K sold.

Michael Gelband first reported a position in MANE in Q1 2026 and held it in 1 quarter. The position peaked at $212K in Q1 2026. 163 funds tracked by Wall St. Rank hold MANE as of Q2 2026.

Michael Gelband reported no remaining Veradermics Inc position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 3,358 Veradermics Inc shares in Q2 2026, an estimated $212K.
Michael Gelband first reported a position in Veradermics Inc in Q1 2026 and held it in 1 quarter.
Michael Gelband's Veradermics Inc position peaked at $212K in Q1 2026.
163 funds tracked by Wall St. Rank held Veradermics Inc as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.